GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
What does it do?
GE HealthCare makes the machines hospitals use to see inside your body — think MRI scanners, CT scanners, and ultrasound devices. If you've ever had a scan at a hospital, there's a good chance the machine had a GE logo on it. Beyond the hardware, they also sell the software that helps doctors read those images and the radioactive tracers used in certain types of cancer and heart scans. They spun off from the old General Electric conglomerate in January 2023 and now operate as a standalone healthcare company.
GE HealthCare is one of the largest medical imaging companies on the planet, competing directly with Siemens Healthineers and Philips in a market where hospitals can't really opt out of buying equipment. The company is at the center of a major trend right now: AI tools being built directly into diagnostic machines to help doctors catch diseases faster and more accurately. With an aging global population driving higher demand for scans and procedures, the underlying business has a strong structural tailwind that makes it interesting to long-term investors.
How does it make money?
GE HealthCare generated $20.6 billion in revenue in its latest fiscal year, up from $19.7 billion the prior year — roughly a 5% increase. The bulk of revenue comes from selling imaging equipment like CT and MRI machines to hospitals and clinics around the world. They also earn recurring revenue through service contracts — hospitals pay annually to keep these expensive machines maintained and updated — which provides a steady, predictable income stream. Their Pharmaceutical Diagnostics segment sells contrast agents and tracers used in scans, adding a consumables business that keeps customers coming back regardless of whether they're buying new machines.
Why do investors care?
Investors are interested because GE HealthCare has the rare combination of a large installed base of machines already in hospitals and a growing software and AI layer being built on top of that hardware. The pitch is that once a hospital buys your scanner, you can keep selling them upgrades, software licenses, and service contracts for 10-plus years. The company is also expanding its AI-powered imaging tools under its 'Edison' platform, which could command premium pricing as hospitals seek better diagnostic accuracy. For the thesis to work, GEHC needs to successfully transition from a hardware seller to a recurring-revenue technology company — that shift is the key thing to watch.
Deep Dive
MemberA full investor briefing on GE HealthCare Technologies Inc. — history, leadership, risks, and outlook.